Mesoblast Ryoncil Revenue Crushes Estimates With $115 Million Debut Year
As seen on the 24/7 Wall St. homepage on July 30, 2026.
Mesoblast posted $115 million in first-year Ryoncil revenue, crushing the $52 million estimate, but the full-year tally obscures a stunning second-half acceleration that sent $66.5 million in sales through the door as the cell therapy gained traction across major pediatric transplant centers. The biotech has nearly three years of runway on $103 million in cash before burning through its fuel, buying time for adult label extensions and a Duchenne muscular dystrophy registrational trial to potentially unlock blockbuster potential.
Continue ReadingShow less
Ryoncil's first full year on the market generated $115 million in revenue, more than double the $52 million analyst estimate, and the headline number actually understates the momentum underneath it. A full $66.5 million of that total flowed in during the second half alone, signaling that the cell therapy was still accelerating as pediatric transplant centers continued to adopt it — a trajectory that matters far more to long-term investors than the annual total.
On the earnings-per-share front, Mesoblast reported $0.00 for Q2 2026 against an estimate of -$0.05, continuing a recent pattern of beating or meeting consensus that stretches back through Q2 2025, when the company similarly reported $0.00 against a -$0.14 estimate. That steady drift toward breakeven reflects the commercial ramp rather than any single quarter's cost management.
Sponsored
_________________________________
What's Your Number...?
Here's a question most people 5y from retirement can't answer: at your current savings rate, how much do you need, and how long will it actually last? A good advisor can put a date on that in a single meeting. SmartAsset's free quiz matches you with up to three fiduciary advisors serving your area, so you can get YOUR retirement number now (sponsor)
__________________________________________
With $103 million in cash on hand, Mesoblast has nearly three years of runway to advance two potentially significant programs: adult label extensions for Ryoncil and a registrational trial in Duchenne muscular dystrophy. Both represent opportunities that could meaningfully expand the company's addressable market beyond the pediatric transplant setting where Ryoncil first launched.